Two oncology biosimilars from Thousand Oaks-based biotech giant Amgen hit the U.S. market July 18, copying Roche treatments for several types of cancer. Mvasi, Amgen’s second biosimilar to reach the market and the first oncology biosimilar to be approved by the U.S. Food and Drug Administration, was released to treat five types of cancer, including…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
